AusPharm CE Hormone therapy 23/09/10. Hormone therapy
|
|
- Sophia Banks
- 5 years ago
- Views:
Transcription
1 Hormone therapy Learning objectives: Assess options to address quality of life and health concerns of menopausal women Outline indications for hormone therapy Counsel women on the risks and benefits of hormone therapy Direct patients to evidence-based information resources Introduction Understanding the risks and benefits of post-menopausal hormone therapy (HT) is a complex area with significant shifts in the evidence over the last twenty years. Since the 1960s oestrogen has been prescribed as an effective treatment for vasomotor symptoms associated with menopause. It is interesting to reflect on the early marketing of the then-called hormone replacement therapy where it was viewed as a revolutionary breakthrough for women. In 1966 New York gynaecologist Robert Wilson stated in his book Feminine Forever that "menopause is a hormone deficiency disease, curable and totally preventable, and that every woman, no matter what her age, can safely lead a fully-sexed life for her entire life." 1 He described oestrogen therapy as the fountain of youth that would prevent women from experiencing the "tragedy" of menopause, which would leave them dried up, sexless, and depressed. The use of oestrogen declined in the mid-1970s when endometrial cancer was linked to unopposed oestrogen use. During the 1980s use increased again when it was shown that the addition of progestogens was protective. During the 1990s, HT was being used to reduce heart disease, in addition to treating menopausal symptoms. The Women's Health Initiative (WHI) Study first published in 2002 has had a major impact on the understanding of the actual benefits and risks of menopausal hormone therapy. 2 Menopause Menopause occurs when the ageing ovaries become less responsive to follicle-stimulating hormone (FSH) and luteinising hormone (LH), resulting in fewer ovulations and decreasing amounts of circulating progesterone and oestrogen. Women are considered to be perimenopausal when menstrual regularity discontinues, typically around 51 years of age. Women with early or surgical menopause may have worse or persistent symptoms. Up to 80% of perimenopausal and early postmenopausal women will experience some menopause symptoms, hot flushes being the most common. Whilst oestrogen remains the most effective treatment,
2 concerns around the adverse effects of hormone replacement therapy have lead to increased interest in other therapies for improving menopausal symptoms. Menopausal symptoms include hot flushes, night sweats, vaginal dryness, impaired sexual function and sleep disorders. Other common symptoms associated with menopause include difficulty concentrating, fatigue, irritability, headaches and musculoskeletal discomfort. The average duration of these symptoms is 5.5 years, although symptom duration can range anywhere from five months to 10 years, with the severity varying from mild to severe. When menstruation ceases for more than one year, women are considered to be post-menopausal. After menopause, symptoms will decline in most women. However symptoms may continue in around 2% of women into their 70s. 3 Hormone therapy Oestrogen is considered the most effective known hormone therapy. However it is neither appropriate nor desirable for every symptomatic woman. Other hormonal treatments include progestins, raloxifene (a selective oestrogen receptor modulator or SERM) and tibolone. Indications The principle indication for hormone therapy is the treatment of vasomotor symptoms (hot flushes and night sweats) associated with menopause. Vasomotor symptoms affect up to 80% of women and typically begin in perimenopause. Current evidence suggests that the benefits generally outweigh the risks for healthy women with bothersome symptoms who decide to take HT at the time of menopause. In the late 1980s around 40 retrospective observational studies suggested that HT reduced the risk of heart attack by 50%. This led to the conventional wisdom that all women should use HT for heart protection, unless there was a reason not to do so. Women with cardiovascular disease risk factors, especially previous myocardial infarction, stroke, hypertension or diabetes, we encouraged to use HT even in the absence of vasomotor symptoms. Then came two randomised controlled trials designed to evaluate cardioprotection by hormone therapy: HERS, 4 a secondary prevention trial; and WHI, a primary prevention trial. Current data does not support a role for HT in the primary or secondary prevention of heart disease. Benefits Oestrogen is the most effective treatment for hot flushes. Oestrogen also improves bone mineral density and vaginal dryness, and possibly mood and sleep disturbances. Vasomotor symptoms
3 Oestrogen with or without a progestogen significantly lowers the frequency and severity of hot flushes. About 80% of women will experience relief from symptoms with hormone therapy. 5 Treatment with oestrogen reduces the number of hot flushes by about 18 per week, compared with placebo. 6 Tibolone also alleviates post-menopausal vasomotor symptoms. It should also be noted that the placebo effect in studies of hot flush treatments is as high as 50%. 6,7 Cardiovascular Oral oestrogen initiated around the time of menopause may provide cardioprotection by reducing the progression of atherosclerotic plaques. Administration of oestrogen many years after menopause may disrupt established plaques, leading to adverse cardiovascular outcomes. 8 In WHI study the increase in cardiovascular events only reached statistical significance in the 70 to 79 year old group on combined HT. Urogenital system Vaginal dryness and associated symptoms such as pruritus, bleeding, dysuria, urinary urgency and recurrent urinary tract infections affect up to 75% of postmenopausal women. Urogenital atrophy is generally progressive in the absence of treatment. Very low doses of vaginal oestradiol relieve symptoms and normalise vaginal atrophy associated with menopause. A Cochrane review concluded that vaginal oestrogen preparations including creams, rings, and tablets were equally effective in treating the symptoms of vaginal atrophy. 9 Low doses of oestrogen cream are effective when used one to three times a week. Tibolone improves urogenital atrophy. Vaginal oestrogen may reduce the symptoms of overactive bladder, such as urgency and frequency. It can also reduce the likelihood of recurrent urinary tract infections in postmenopausal women. Oral HT was reported to increase stress and urge incontinence in the WHI trial. 10 Bone Hormone therapy is effective at both preventing and treating osteoporosis. Oestrogen with or without progestogen prevents early postmenopausal bone loss and augments bone mass in late menopause as effectively as bisphosphonates. In addition, oestrogen alone or in combination with a progestogen can prevent hip and vertebral factures. In the WHI study there was a 33% reduction in hip fractures after an average follow-up of 5.6 years. 11 Unfortunately this benefit does not persist after HT discontinuation. Tibolone is considered second line therapy for prevention of BMD loss in postmenopausal women at high risk of osteoporotic fractures. It significantly reduces vertebral and non-vertebral fractures in women over the age of 60 years with osteoporosis. Raloxifene improves BMD and reduces vertebral but not hip fractures. Breast cancer Raloxifene and tibolone decreases breast cancer risk. Colon cancer Combined HT decreases colon cancer risk. Tibolone is associated with a reduction of colon cancer.
4 Joint pain Oestrogen exerts a protective effect on osteoarthritis. The Women s International Study of long Duration Oestrogen after Menopause (WISDOM) showed a significant reduction in joint pain in the HT groups compared with placebo. 12 Quality of life Overall quality of life was also improved in the WISDOM study with combined HT started many years after menopause. 12 Health-related quality of life is improved through decreased symptoms, sleep enhancement and possibly mood enhancement. Risks Hormone therapy is associated with an increased incidence of venous thromboembolic events, pulmonary embolus, stroke, breast cancer and gallbladder disease. The Million Women Study showed an association with an increased risk of heart disease, thromboembolic disease and stroke, and breast cancer. 13 Event Increased risk per 10,000 women per year using HT Oestrogen only Oestrogen and progestogen Stroke 12 extra 8 extra VTE 8 extra 18 extra Coronary Heart Disease No increase 6 extra CHD events Breast Cancer No increase 8 extra Endometrial Cancer n/a No increased risk Colorectal Cancer 1 extra 7 less Hip fractures 7 less 5 less Total fractures 53 less 47 less Cardiovascular Retrospective epidemiological studies reported a 50% decrease in heart disease in women who use HT. 14 this observed reduction in CHD was thought secondary to beneficial effects of HT on lipids and direct actions on blood vessels. However most studies included women in their 50s and were at lower risk of heart disease than nonusers. Despite the limitations of the WHI, it remains clear that hormone therapy initiated at or after the median age of women in this study (63 years) increases the risk of detrimental vascular outcomes. 15 The WHI trial of oestrogen and progestogen therapy demonstrated an increased risk of CHD in postmenopausal women. The hazard ratio for increased CHD was 1.3 and 1.4 for stroke. The absolute risk per 10,000 woman-years attributable to HT was small, with seven more CHD events and eight strokes. In the WHI trial of unopposed oestrogen a small increased risk of stroke and VTE was observed, but no increased risk of CHD. Reanalysis of data from the WHI has confirmed that the increased risk of CHD occurs principally in older women and in women taking HT for more than 5 years. No increased risk of CHD was seen in women between the ages of 50 and 59 or in those within 10 years of menopause. 16
5 The risk of stroke is increased with HT, although the absolute excess risk of stroke in younger women is minimal. Analysis of WHI data has shown that oestrogen therapy alone for an average of 7 years increases the risk of stroke in older women. 17 Tibolone does not increase the risk of CHD events. There is no increase in stroke with the use of raloxifene. Tibolone increases the risk of stroke in older women, but not younger women. Breast cancer The lifetime risk of invasive breast cancer is 12%. Risk factors for breast cancer age, early menarche, late menopause, family history, and prior breast disease. Pregnancy before the age of 30 years is associated with a reduced risk. Current data suggests the increased risk of breast cancer on combined HT is four per 10,000 women-years, i.e. two per 1,000 women after 5 years. 6 WHI reported an increased relative risk (RR) of breast cancer with long-term combined HT of 1.53 after a median of 8 years. 2 However, the risk of breast cancer does not increase with oral or transdermal application of oestrogen when used for less than 5 years. 18,19 Analysis has shown that there was no significant increase in breast cancer among those who initiated combined HT for the first time during the 7 years of WHI. 20 In fact, the use of oestrogen alone for less than 5 years may reduce the risk of breast cancer in women starting therapy many years after the onset of menopause. It is important to put this in perspective with other risk factors include lifestyle issues. The relative risk seen in WHI for breast cancer was This is similar to a late menopause of 55 years or more (RR 1.22), three alcohol drinks per day (RR 1.4) or nulliparity (RR 1.67). Factor Estimated relative risk High fat diet 2.0 First pregnancy >30 years 1.48 BMI> Non breast feeding 1.2 Alcohol use > 5g/ day 1.16 Delayed menopause 1.14 Hormone therapy overall 1.24 Current user for 5 years 2.0 In general consensus is that HT should not be prescribed to women with a history of breast cancer and should only be used by women at high risk after a careful assessment of risks and benefits. Tibolone increases the risk of breast cancer recurrence. Endometrial cancer No difference in the risk of endometrial cancer was seen with combined oestrogen and progestogen therapy compared with placebo in WHI. 21 Ovarian cancer
6 No significant difference in the risk of ovarian cancer was seen with combined oestrogen and progestogen therapy compared with placebo in WHI. 21 Colorectal cancer The WHI identified a reduced risk of colorectal cancer in women on combined HT, but no beneficial affect was seen in women who had undergone hysterectomy on oestrogen alone. VTE HT increases the risk of venous thromboembolic events (VTE) approximately 2-fold. Raloxifene also increases the incidence of VTE. Dose and duration The lowest effective dose of hormone therapy should be used to minimise adverse effects for the shortest duration to minimise symptoms. For younger women aged less than 60 years in the early postmenopausal period, oestrogen therapy may be cardioprotective. 22 This window of therapeutic opportunity should be explained to patients when discussing the risk and benefits of HT. HT can be stopped abruptly or tapered. 23 Regardless some women will experience recurrence of vasomotor symptoms and will restart HT. Implications for practice Community and accredited pharmacists are often asked for advice on the use of hormone therapy. Best available evidence supports the use of hormone therapy for management of severe vasomotor symptoms. While oestrogen remains the most effective therapy for hot flushes, the risk/benefit needs to be considered, together with patient preferences. Recommendations should consider the patient's personal choice, symptom severity, existing risks, age and years since menopause. Pharmacists should discuss the potential benefits, adverse effects and the uncertainties of hormone therapy and advice patients on where to access further information. Patients and pharmacists should periodically assess the treatment outcomes. Further reading and patient information NPS News 64: Therapeutic choices for menopausal symptoms NPS Prescribing Practice Review 47: Managing menopausal symptoms The Jean Hailes Foundation for Women's Health Debbie Rigby September 2010
7 MCQs 1) Regarding the use of oestrogen therapy for the management of hot flushes, which of the following statements is incorrect? a) cardiovascular disease may be reduced when HT is initiated near menopause b) oestrogen therapy is the most effective therapy for menopausal symptoms c) breast cancer risk decreases after several years of combined HT d) no increase in breast cancer risk is seen with oestrogen-only HT 2) Which of the following statements regarding the absolute risks of HT is correct? a) Absolute risks of HT decrease with age b) Combined HT does not affect the absolute risk of breast cancer c) Oestrogen therapy alone does not affect the absolute risk of breast cancer d) Duration of therapy of HT has no affect on the absolute risk of breast cancer 3) The balance of risks and benefits for oestrogen-alone therapy is more favourable for women without a uterus. a) True b) False 4) Which of the following statements regarding the risk of breast cancer is incorrect? a) Long-term use of HT is associated with an increased risk of breast cancer b) Oestrogen-alone therapy increases the risk of breast cancer after 15 years of current use c) Combined oestrogen and progestin therapy increases the risk of breast cancer after 7 years of current use d) The risk of breast cancer is similar for HT and 3 standard drinks of alcohol per day 5) Regarding the WHI study, which of the following statements is correct? After 5 years of combined oestrogen and progestogen therapy there is: a) Reduction in fractures, no overall cardiovascular benefit, an increased risk of breast cancer and thromboembolism b) Reduction in fractures, decreased cardiovascular risk, an increased risk of breast cancer and thromboembolism c) Reduction in fractures, no overall cardiovascular benefit, an increased risk of breast cancer, decreased risk of thromboembolism d) Increased risk of hip fractures, no overall cardiovascular benefit, an increased risk of breast cancer and thromboembolism 6) In the WHI, a reduced risk of which type of cancer was observed in women on combined HT? a) Endometrial cancer b) Colorectal cancer c) Ovarian cancer d) All of the above
8 References 1 Wilson R. Feminine Forever. New York: M. Evans and Company; Writing Group for the Women s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women s Health Initiative randomized controlled trial. JAMA 2002;288: Ockene JK, Barad DH, Cochrane BB, et al. Symptom experience after discontinuing use of estrogen plus progestin. JAMA. 2005;294: Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280: Speroff L, Haney AF, Gilbert RD, et al. Efficacy of a new, oral estradiol acetate formulation for relief of menopause symptoms. Menopause 2006;13: MacLennan AH, Broadbent JL, Lester S, et al. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004;CD Stearns V. Clinical update: new treatments for hot flushes. Lancet 2007;369: MacLennan AH, Sturdee DW. Long-term trials of HRT for cardioprotection - is this as good as it gets? Climacteric. 2007;10: Suckling J, Kennedy R, Lethaby A, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. The Cochrane Database of Systematic Reviews 2006, Issue 4. Art No. CD DOI: / CD pub2. 10 Hendrix SL, Cochrane BB, Nygaard IE, Handa VL, Barnabei VM, Iglesia C, et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA 2005;293: Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, et al; Women s Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density. JAMA 2003;290: Welton AJ, Vickers MR, Kim J et al. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ 2008;337:a Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003;362: Stampfer MJ, Colditz GA, Willet WC, Manson JE, Rosner B, Speizer FE, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses Health Study. N Engl J Med 1991;325: Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al. Effects of conjugated equine estrogen on stroke in thewomen s Health Initiative. Circulation. 2006;113: Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297: Women s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women s Health Initiative randomized controlled trial. JAMA 2004;291: Wong T, Shah NR. Breast cancer from oral and transdermal estradiol: a cohort study of Finnish women. Women's Health. 2007;3: Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estrogen only therapy. Obstet Gynecol. 2006;108: MacLennan AH. Evidence-based review of therapies at the menopause. Int J Evid Based Healthcare 2009;7: Anderson GG, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M, et al; Women s Health Initiative Investigators. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women s Health Initiative randomized trial. JAMA 2003;290: Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297: Lindh-Åstrand L et al. A randomized controlled study of taper-down or abrupt discontinuation of hormone therapy in women treated for vasomotor symptoms. Menopause 2010 Jan/Feb; 17:72.
Menopause and HRT. John Smiddy and Alistair Ledsam
Menopause and HRT John Smiddy and Alistair Ledsam Menopause The cessation of menstruation Diagnosed retrospectively after 1 year of amenorrhoea Average age 51 in the UK Normal physiology - Menstruation
More informationLearning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories
Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen
More informationMenopausal hormone therapy currently has no evidence-based role for
IN PERSPECTIVE HT and CVD Prevention: From Myth to Reality Nanette K. Wenger, M.D. What the studies show, in a nutshell The impact on coronary prevention Alternative solutions Professor of Medicine (Cardiology),
More informationMenopause management NICE Implementation
Menopause management NICE Implementation Dr Paula Briggs Consultant in Sexual & Reproductive Health Southport and Ormskirk NHS Hospital Trust Why a NICE guideline (NG 23) Media reports about HRT have not
More informationWHI Estrogen--Progestin vs. Placebo (Women with intact uterus)
HORMONE REPLACEMENT THERAPY In the historical period it was commonly held that estrogen had two principal benefits to postmenopausal women: 1) To alleviate the constitutional symptoms related to the climacteric
More informationSERMS, Hormone Therapy and Calcitonin
SERMS, Hormone Therapy and Calcitonin Tiffany Kim, MD Clinical Fellow VA Advanced Women s Health UCSF Endocrinology and Metabolism I have nothing to disclose Thanks to Clifford Rosen and Steven Cummings
More informationEstrogen and progestogen therapy in postmenopausal women
Estrogen and progestogen therapy in postmenopausal women The Practice Committee of the American Society for Reproductive Medicine American Society for Reproductive Medicine, Birmingham, Alabama Hormone
More informationHRT in Perimenopausal Women. Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College
HRT in Perimenopausal Women Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College 1 This is the Change But the CHANGE is not a disease 2 Introduction With a marked increase in longevity, women now
More informationHRT and bone health. Management of osteoporosis and controversial issues. Delfin A. Tan, MD
Strong Bone Asia V. Osteoporosis in ASEAN (+), Danang, Vietnam, 3 August 2013 Management of osteoporosis and controversial issues HRT and bone health Delfin A. Tan, MD Section of Reproductive Endocrinology
More informationHormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals
Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals Literature Review (January 2009) Hormone Therapy for Women Women's Health
More informationWomen s Health: Managing Menopause. Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School
Women s Health: Managing Menopause Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School Disclosures I have no conflicts of interest. Learning Objectives 1. Apply strategies to help
More informationMenopause & HRT. Rosie & Alex. Image:
Menopause & HRT Rosie & Alex Image: http://www.keepcalm-o-matic.co.uk/ Menopause The permanent cessation of menstruation for 12 months When does it happen? Average age 51 Image: Nature Medicine - 12, 612-613
More informationMenopause: diagnosis and management NICE guideline NG23. Published November 2015
Menopause: diagnosis and management NICE guideline NG23 Published November 2015 1 Full title: Menopause : diagnosis and management Available at: http://www.nice.org.uk/guidance/ng23 Guideline published
More informationThe Practice Committee of the American Society for Reproductive Medicine,
FERTILITY AND STERILITY VOL. 81, NO. 1, JANUARY 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. PRACTICE COMMITTEE Estrogen
More informationVirtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11
Virtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11 Clinical Pearl Post Women's Health Initiative Menopausal Women and Hormone Therapy by JoAnn V. Pinkerton,
More informationBefore you prescribe
Initiating hormone replacement therapy (HRT) / menopausal hormone therapy (MHT) Dr Sonia Davison Jean Hailes Consultant Endocrinologist Before you prescribe Ensure there are no contraindications to HRT/MHT
More informationKathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School
Update: Hormones and Cardiovascular Disease in Women Kathryn M. Rexrode, MD, MPH Assistant Professor Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Overview Review
More information2017 Position Statement of Hormone Therapy of NAMS: overview SHELAGH LARSON, MS, RNC WHNP, NCMP ACCLAIM, JPS HEALTH NETWORK
2017 Position Statement of Hormone Therapy of NAMS: overview SHELAGH LARSON, MS, RNC WHNP, NCMP ACCLAIM, JPS HEALTH NETWORK WHI the only large, long-term RCT of HT in women aged 50 to 79 years, Drug trail
More informationMenopause & HRT. Matt McKenna Elliot Davis
Menopause & HRT Matt McKenna Elliot Davis Menopause Before age 40: Premature Menopause After 12 months clinical diagnosis made Depletion of Ovarian Follicles Oestrogen Progesterone LH FSH Spontaneous Amemorrhoea
More informationBenton Franklin County Medical Society 31st Annual CME Seminar
Management of Current HT/ET and SERM Recommendations Benton Franklin County Medical Society 31st Annual CME Seminar February 21, 2015 Kennewick, Washington Spokane steoporosis Dr. Lynn Kohlmeier Lynn Kohlmeier,
More informationSex, hormones and the heart
Sex, hormones and the heart Dr Louise Newson BSc(Hons) MBChB(Hons) MRCP FRCGP www.menopausedoctor.co.uk #IandA2017 Declaration I have had financial relationships (lecturer, writer, member of advisory boards
More informationMENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE?
MENOPAUSE WHAT S NEW? WHAT S SAFE? I have no disclosures Sara Whetstone, MD, MHS OBJECTIVES To describe risks of HT by age and menopause onset To recommend specific HT regimen for women who undergo early
More informationOVERVIEW OF MENOPAUSE
OVERVIEW OF MENOPAUSE Nicole Budrys, MD, MPH Reproductive Endocrinology Michigan Center for Fertility and Women s Health Presented at SEMCME March 13,2019 Objectives Define menopause Etiology of menopause
More informationSummary of the risk management plan (RMP) for Duavive (conjugated oestrogens / bazedoxifene)
EMA/679870/2014 Summary of the risk management plan (RMP) for Duavive (conjugated oestrogens / bazedoxifene) This is a summary of the risk management plan (RMP) for Duavive, which details the measures
More informationHRT & Menopause Where Do We Stand Now?
HRT & Menopause Where Do We Stand Now? Mrs. SY Hussain Consultant Gynaecologist The Holly Private Hospital Spire Roding Hospital The Wellington Hospital Discussion Points Discuss Recommendations made by
More informationHKCOG Guidelines. Guidelines for the Administration of Hormone Replacement Therapy. Number 2 Revised November BENEFITS OF HRT
HKCOG Guidelines Guidelines for the Administration of Hormone Replacement Therapy Number 2 Revised November 2006 Published by The Hong Kong College of Obstetricians and Gynaecologists A Foundation College
More informationWHI, HERS y otros estudios: Su significado en la clinica diária. Manuel Neves-e-Castro
WHI, HERS y otros estudios: Su significado en la clinica diária III Congreso Ecuatoriano de Climaterio Menopausia y Osteoporosis por Manuel Neves-e-Castro (Lisboa-Portugal) Julho, 2003 Machala The published
More informationPrior disclosures past 3 years Consultant for Pfizer University of Virginia received Grants/research support from TherapeuticsMD
Prior disclosures past 3 years Consultant for Pfizer University of Virginia received Grants/research support from TherapeuticsMD JoAnn V. Pinkerton, MD Professor of Obstetrics and Gynecology Director,
More informationNorth American Menopause Society (NAMS)
North American Menopause Society (NAMS) 2012 Hormone Therapy Position Statement Cynthia B. Evans, MD Assistant Professor-Clinical Department of Obstetrics and Gynecology The Ohio State University College
More informationPostmenopausal hormone therapy - cardiac disease risks and benefits
Postmenopausal hormone therapy - cardiac disease risks and benefits Tomi S. Mikkola, MD Helsinki University Central Hospital Department of Obstetrics and Gynecology Helsinki, Finland Disclosures Speaker/consulting
More informationThe preferred treatment for osteoporosis
Alternate Options to Hormone Replacement Therapy for Osteoporosis James R. Shoemaker, DO Andrea B. Klemes, DO This presentation, developed from a symposium lecture at the 40th Annual Convention of the
More informationPractical recommendations for hormone replacement therapy in the peri- and postmenopause
CLIMACTERIC 2004;7:in press Practical recommendations for hormone replacement therapy in the peri- and postmenopause Recommendations from an Expert Workshop, February 2004 Henry Burger, Australia; David
More informationMENOPAUSAL HORMONE THERAPY 2016
MENOPAUSAL HORMONE THERAPY 2016 Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA NICE provides the National Health Service advice on effective, good value healthcare.
More informationHT: Where do we stand after WHI?
HT: Where do we stand after WHI? Hormone therapy and cardiovascular disease risk Experimental and clinical evidence indicate that hormone therapy (HT) reduces the risk of cardiovascular disease (CVD) Women
More informationManaging menopause in Primary Care and recent advances in HRT
Managing menopause in Primary Care and recent advances in HRT Raj Saha, MD, DMRT, FRCOG PG Cert. Advanced Gynaecology Endoscopy Consultant Gynaecologist Heart of England NHS Foundation Trust Spire Parkway
More informationHormone therapy. Dr. med. Frank Luzuy
Hormone therapy Dr. med. Frank Luzuy Reasons for Initiating/Continuing HT* Menopause-Related Symptoms Osteoporosis, Bone Loss, Fracture Prevention Doctor Prescribed It, Told Me to Take It Cardiovascular
More informationMs. Y. Outline. Updates of SERMs and Estrogen
Ms. Y Updates of SERMs and Estrogen Steven R. Cummings, MD, FACP San Francisco Coordinating Center CPMC Research Institute and UCSF Support from Lilly, Pfizer, Berlex 55 y.o. woman with mild hypertension
More informationPost-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018
Post-menopausal hormone replacement therapy Evan Klass, MD May 17, 2018 Are we really still talking about this? Are we really still talking about this? 1960-1975- estrogen prescriptions doubled. Pharma
More informationManaging menopause in Primary Care and recent advances in HRT
Managing menopause in Primary Care and recent advances in HRT Raj Saha, MD, DMRT, FRCOG Consultant Gynaecologist Heart of England NHS Foundation Trust rajsaha1@yahoo.co.uk Content of today s talk Aims
More informationHORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer
HORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer -- PART 1 -- Definitions HRT hormone replacement therapy HT genome therapy ERT estrogen replacement therapy ET estrogen EPT estrogen progesterone therapy
More informationOB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc.
OB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc. Napa, California IMPORTANT SAFETY INFORMATION ABOUT EVAMIST: WARNING: ENDOMETRIAL CANCER,
More informationYear: Issue 1 Obs/Gyne The silent epidemic: Postmenopausal vaginal atrophy
Year: 2013 - Issue 1 Obs/Gyne The silent epidemic: Postmenopausal vaginal atrophy By: Dr David W Sturdee, Immediate past President International Menopause Society and Hon Consultant Gynaecologist, Solihull
More information22/09/2014. Menopause Management. Menopause. Menopause symptoms
Menopause Management Dr Sonia Davison Jean Hailes for Women s Health Menopause Time of last menstrual period - average age 51 Premature Menopause: occurs before age 40 Perimenopause (menopause transition):
More informationAppendix: Reference Table of HT Brand Names
Appendix: Reference Table of HT Brand Names This is a full reference table in alphabetical order, of Brand Name drugs used in HT. It is the basis for prescription advice throughout this handbook. Drug
More informationEstrogen (conjugated estrogens & ethinyl estradiol) Addition to the List
Estrogen (conjugated estrogens & ethinyl estradiol) Addition to the List Note: Commonly prescribed medication. Literature question Is estrogen effective and safe? Are conjugated estrogens effective and
More informationCLINICAL PROCEEDINGS. New Dynamics in Health Care : Hormone Therapy and Menopause Care THE PHYSIOLOGY OF MENOPAUSE INDIVIDUALIZING HORMONE THERAPY
A R H CLINICAL!!! P PROCEEDINGS A PUBLICATION OF THE ASSOCIATION OF REPRODUCTIVE HEALTH PROFESSIONALS July 2004 New Dynamics in Health Care : Hormone Therapy and Menopause Care 3 13 THE PHYSIOLOGY OF MENOPAUSE
More informationHKCOG Guidelines. Guidelines for the Administration of Hormone Replacement Therapy. Number 2 revised January 2003
HKCOG Guidelines Guidelines for the Administration of Hormone Replacement Therapy Number 2 revised January 2003 published by The Hong Kong College of Obstetricians and Gynaecologists A Foundation College
More informationA Practitioner s Toolkit for the Management of the Menopause
Medicine, Nursing and Health Sciences A Practitioner s Toolkit for the Management of the Menopause Developed by the Women s Health Research Program School of Public Health and Preventive Medicine Monash
More information06-Mar-17. Premature menopause. Menopause. Premature menopause. Menstrual cycle oestradiol. Premature menopause. Prevalence ~1% Higher incidence:
Menopause Dr Sonia Davison MBBS FRACP PhD Endocrinologist and Clinical Fellow, Jean Hailes for Women s Health Women s Health Research Program, Monash University = the last natural menstrual period depletion
More informationSupplementary Online Content
Supplementary Online Content Gartlehner G, Patel SV, Feltner C, et al. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women: Evidence Report and Systematic Review for
More informationSomething has changed? The literature from 2008 to present?
Something has changed? The literature from 2008 to present? Elina Hemminki National Institute for Health and Welfare, Helsinki, Finland Rome Oct 7, 2011: Post-menopausal hormone therapy and women's information
More informationHormone Replacement Therapy (HRT) Benefits & Risks - The Facts
Hormone Replacement Therapy (HRT) Benefits & Risks - The Facts HRT is a prescription only treatment that replaces some of the lost oestrogen and progesterone hormones which occur during menopause. It can
More informationUPDATE: Women s Health Issues
UPDATE: Women s Health Issues Renee B. Alexis, MD, MBA, MPH, FACOG Associate Professor Department of OBGYN Kiran C. Patel College of Osteopathic Medicine Disclosure of Conflicts of Interest I have no financial
More informationPostmenopausal hormone therapy and cancer risk
International Congress Series 1279 (2005) 133 140 www.ics-elsevier.com Postmenopausal hormone therapy and cancer risk P. Kenemans*, R.A. Verstraeten, R.H.M. Verheijen Department of Obstetrics and Gynaecology,
More informationMenopause - a summary of management
Page 1 of 5 Menopause - a summary of management Original article by: May Su Resources Menopause treatment algorithm The Jean Hales Foundation for women's heath. Menopause, a treatment algorithm. (Australian
More informationCLINICIAN INTERVIEW CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN
CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN Nanette K. Wenger, MD, is a recognized authority on women and coronary heart disease. She chaired the US National Heart, Lung, and Blood Institute conference
More informationMenopausal Management: What Has Changed?
Menopausal Management: What Has Changed? Julia V. Johnson, M.D. Professor and Chair, OB/GYN University of Massachusetts Medical School UMass Memorial Medical Center Conflicts of Interest None Learning
More informationCOMMENTARY: DATA ANALYSIS METHODS AND THE RELIABILITY OF ANALYTIC EPIDEMIOLOGIC RESEARCH. Ross L. Prentice. Fred Hutchinson Cancer Research Center
COMMENTARY: DATA ANALYSIS METHODS AND THE RELIABILITY OF ANALYTIC EPIDEMIOLOGIC RESEARCH Ross L. Prentice Fred Hutchinson Cancer Research Center 1100 Fairview Avenue North, M3-A410, POB 19024, Seattle,
More informationNICE guideline Published: 12 November 2015 nice.org.uk/guidance/ng23
Menopause: diagnosis and management NICE guideline Published: 12 November 2015 nice.org.uk/guidance/ng23 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationPotential dangers of hormone replacement therapy in women at high risk
ESC meeting, Stockholm, August 30, 16.30-18.00, 2010 Potential dangers of hormone replacement therapy in women at high risk Karin Schenck-Gustafsson MD, PhD, FESC Professor, Chief consultant Department
More informationCASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology
CASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology A 49-year-old woman complains of irregular menses over the past 6 months, feelings of inadequacy, vaginal dryness, difficulty sleeping, and episodes
More informationOutline. Estrogens and SERMS The forgotten few! How Does Estrogen Work in Bone? Its Complex!!! 6/14/2013
Outline Estrogens and SERMS The forgotten few! Clifford J Rosen MD rosenc@mmc.org Physiology of Estrogen and estrogen receptors Actions of estrogen on bone BMD, fracture, other off target effects Cohort
More informationPostmenopausal hormones and coronary artery disease: potential benefits and risks
CLIMACTERIC 2007;10(Suppl 2):21 26 Postmenopausal hormones and coronary artery disease: potential benefits and risks R. A. Department of Obstetrics and Gynecology, Columbia University, New York, New York,
More informationWEIGHING UP THE RISKS OF HRT. Department of Endocrinology Chris Hani Baragwanath Academic Hospital
WEIGHING UP THE RISKS OF HRT V. Nicolaou Department of Endocrinology Chris Hani Baragwanath Academic Hospital Background Issues surrounding post menopausal hormonal therapy (PMHT) are complex given: Increased
More informationJames H. Liu, M.D. Arthur H. Bill Professor Chair of Reproductive Biology Dept of Obstetrics and Gynecology
Disclosure Estrogen Therapy After Postmenopausal Hysterectomy: Issues, Challenges, Risks/Benefits James H. Liu, M.D. Arthur H. Bill Professor Chair of Reproductive Biology Dept of Obstetrics and Gynecology
More informationUse of vaginal estrogen in Danish women: a nationwide cross-sectional study
AOGS ORIGINAL RESEARCH ARTICLE Use of vaginal estrogen in Danish women: a nationwide cross-sectional study AMANI MEAIDI 1,, IRINA GOUKASIAN & OEJVIND LIDEGAARD 1 1 Department of Gynecology, Rigshospitalet
More informationHormone therapy. Where are we now? Menopause. Menopause symptoms. Background. Objective. Discussion. Keywords: menopause; hormone therapy
Menopause Helena J Teede Amanda Vincent Hormone therapy Where are we now? Background Menopause is the permanent cessation of menstruation resulting from loss of ovarian follicular activity. The characteristic
More informationHRT. Responding to questions about. The Women s Health Initiative (WHI) is a large, CME Workshop. associated with combined
CME Workshop Responding to questions about HRT By Margaret Burnett, MD, BA(Hon), MA, CCFP, FRCPC The Women s Health Initiative (WHI) is a large, prospective, placebo-controlled trial sponsored by the National
More informationMenopausal hormone therapy includes various forms, Review
Review Annals of Internal Medicine Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendations Heidi
More informationHORMONES AND YOUR HEALTH Charlie Tucker Pharm. D
HORMONES AND YOUR HEALTH Charlie Tucker Pharm. D All of the hormones in your body are designed to work together. This is God s plan. Therefore, if one is altered, or deficient, it will affect the actions
More informationCase Presentation. Learning Objectives. Case Presentation. Case Presentation
Learning Objectives To apply up to date information about the natural history of menopause to improve the care of individual women To counsel women about the risks and benefits of systemic hormone therapy
More informationThe Estrogen Question
The Estrogen Question Hormone Therapy still offers the best relief for menopausal symptoms. Is it right for you? When 49-year-old Lee Ann Dodson heard the news that the Women's Health Initiative (WHI)
More informationBSO, HRT, and ERT. No relevant financial disclosures
BSO, HRT, and ERT Jubilee Brown, MD Professor & Associate Director, Gynecologic Oncology Levine Cancer Institute at the Carolinas HealthCare System Charlotte, North Carolina No relevant financial disclosures
More informationMenopause Matters. Equity Office Staff Seminar 14 November 2018
Menopause Matters Equity Office Staff Seminar 14 November 2018 1 What to expect at menopause How to manage symptoms Support at work Dr Janice Brown Medical lead, The University of Auckland NZ representative,
More informationCoronary Heart Disease in Women Go Red for Women
Coronary Heart Disease in Women Go Red for Women Dr Fiona Stewart Green Lane Cardiovascular Service and National Women s Health Auckland City Hospital Auckland Heart Group Women are Different from Men
More informationTHE RISE AND FALL OF MENOPAUSAL HORMONE THERAPY
Annu. Rev. Public Health 2005. 26:115 40 doi: 10.1146/annurev.publhealth.26.021304.144637 Copyright c 2005 by Annual Reviews. All rights reserved THE RISE AND FALL OF MENOPAUSAL HORMONE THERAPY Elizabeth
More informationThe 6 th Scientific Meeting of the Asia Pacific Menopause Federation
Predicting the menopause The menopause marks the end of ovarian follicular activity and is said to have occurred after 12 months amenorrhoea. The average age of the menopause is between 45 and 60 years
More informationLong-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomised controlled trial
DOI: 10.1111/1471-0528.12598 www.bjog.org Epidemiology Long-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomised controlled trial
More informationApplying Best Evidence to Menopause Management MENOPAUSE IS NOT A DISEASE. Overview. Feminine Forever. Page 1
Applying Best Evidence to Menopause Management Judith Walsh, MD, MPH Division of General Internal Medicine Women s Health Center of Excellence UCSF Overview Natural history of menopause Hormone therapy:
More information5. Summary of Data Reported and Evaluation
326 5. Summary of Data Reported and Evaluation 5.1 Exposure data Combined estrogen progestogen menopausal therapy involves the co-administration of an estrogen and a progestogen to peri- or postmenopausal
More informationWhat s New in Menopause Management. Objectives
What s New in Menopause Management Leslee L. Subak, MD Professor of Obstetrics, Gynecology & Reproductive Science University of California, San Francisco Objectives Define the menopause transition Review
More informationHORMONE REPLACEMENT THERAPY
TRIALS OF HR RUTH (Barrett- Connor et al 29 ) JULY 2006 (Country) mean ± sd, range International trial 67.5 an Placebo component in 67.5 ± 6.7 women with Raloxifene or multiple 67.5 ± 6.6 risk factors
More informationHormones friend or foe? Undertreatment and quality of life. No conflicts of interest to declare
Hormones friend or foe? Undertreatment and quality of life Anette Tønnes Pedersen MD, Ph.D. Consultant, Associate professor Dept. Of Gynecology / Fertility Clinic Rigshospitalet No conflicts of interest
More informationHaemostasis, thrombosis risk and hormone replacement therapy
Haemostasis, thrombosis risk and hormone replacement therapy Serge Motte Brussels 13.05.17 - MY TALK TODAY The coagulation cascade and its regulation Effects of hormone replacement therapy on haemostasis
More informationMenopausal Symptoms. Hormone Therapy Products Available in Canada for the Treatment of. Physician Desk Reference - 3rd Edition
Hormone Therapy Products Available in Canada for the Treatment of Menopausal Symptoms Physician Desk Reference - 3rd Edition A clinical resource provided to you by: The Society of Obstetricians and Gynaecologists
More informationPRESS RELEASE. NICE issues first guideline on menopause to stop women suffering in silence
EMBARGOED UNTIL: 00.01hrs, THURSDAY 12 NOVEMBER 2015 PRESS RELEASE NICE issues first guideline on menopause to stop women suffering in silence More than a million women could benefit from the first NICE
More informationProblems in Postmenopausal Women
Menopausal Management: Where are we in 27? Marcelle I. Cedars, M.D. Professor and Director Division of Reproductive Endocrinology and Infertility UCSF Problems in Postmenopausal Women Vasomotor symptoms
More informationOvaries: In Sickness and Health. Mr N Pisal Consultant Gynaecologist The Portland Hospital
Ovaries: In Sickness and Health Mr N Pisal Consultant Gynaecologist The Portland Hospital Topics for discussion How to assess ovarian function? AMH PCOS Ovarian pain Ovarian cysts Ovarian screening Menopause
More informationPreventing Breast Cancer in HT users by Manuel Neves-e-Castro Portuguese Menopause Society September 2004
Preventing Breast Cancer in HT users by Manuel Neves-e-Castro Portuguese Menopause Society September 2004 I am also PRO!... because HT does not increase breast cancer, and overall, its benefits out weight
More informationApplying Best Evidence to Menopause Management
Applying Best Evidence to Menopause Management Judith Walsh, MD, MPH Division of General Internal Medicine Women s Health Center of Excellence UCSF Overview Natural history of menopause Hormone therapy:
More informationDepartment of Obstetrics and Gynecology, Osaka Medical College, Takatsuki-city, Osaka , Japan. Pituitary gonadotropin, Clinical managament
Original Article Adequate Reduction Degree of Pituitary Gonadotropin Level in the Clinical Management of Short-Term Hormone Replacement Therapy of Women with Menopausal Symptoms Department of Obstetrics
More informationBy Dr Rukhsana Hussain 5 th April 2016
By Dr Rukhsana Hussain 5 th April 2016 1. Is it indicated? Vasomotor symptoms (flushes/sweats) Vaginal atrophy Cycle control (In perimenopause consider low dose COCP (age
More informationDifference between vagifem and yuvafem
Difference between vagifem and yuvafem Generally, when estrogen is prescribed for a postmenopausal woman with a uterus, a progestin should also be considered to reduce the risk of endometrial cancer. Estrogen-alone
More informationOrals,Transdermals, and Other Estrogens in the Perimenopause
Orals,Transdermals, and Other Estrogens in the Perimenopause Cases Denise Black, MD, FRCSC Assistant Professor, Obstetrics, Gynecology and Reproductive Sciences University of Manitoba 6/4/18 197 Faculty/Presenter
More informationHOW TO MAKE SENSE OF MENOPAUSE. by Steven. F. Hotze, M.D.
HOW TO MAKE SENSE OF MENOPAUSE by Steven. F. Hotze, M.D. INTRODUCTION Dr. Hotze is founder of Hotze Health & Wellness Center and author of the book Hormones, Health, and Happiness. He has enabled thousands
More information11/15/2017. Update on HRT. Highgate Private Hospital (Barnet Hospital) Women s Health. Menopause
Update on HRT Miss Moneli Golara Consultant Obstetrician and Gynaecologist MBBS, FRCOG Highgate Private Hospital (Barnet Hospital) E: lauren@medicaladministration.co.uk Women s Health Life expectancy of
More informationBy J. Jayasutha Lecturer Department of Pharmacy Practice SRM College of Pharmacy SRM University
By J. Jayasutha Lecturer Department of Pharmacy Practice SRM College of Pharmacy SRM University Cessation of menstruation as a result of the aging process of or surgical removal of the ovaries; change
More informationDINE AND LEARN ENDOCRINOLOGY PEARLS. Dr. Priya Manjoo, MD, FRCPC Endocrinology, Victoria, BC
DINE AND LEARN ENDOCRINOLOGY PEARLS Dr. Priya Manjoo, MD, FRCPC Endocrinology, Victoria, BC OUTLINE HRT and CVD HRT and Breast Cancer Osteoporosis When to treat How long to treat for Bisphosphonates BMD
More informationVol-5 No-1 Jan-Mar 2012
"Women's Health" is also available at www.squarepharma.com.bd Editorial Board Dr. Omar Akramur Rab MBBS, FCGP, FIAGP Mohammad Hanif M. Pharm, MBA A.H.M. Rashidul Bari M. Pharm, MBA Executive Editor Chowdhury
More informationHormonal Control of Human Reproduction
Hormonal Control of Human Reproduction Bởi: OpenStaxCollege The human male and female reproductive cycles are controlled by the interaction of hormones from the hypothalamus and anterior pituitary with
More information